On September 9, Tianjin Pharmaceutical Co., Ltd. issued an announcement stating that its subsidiary, Tianjin Pharmaceutical Peace, received the Drug Registration Certificate for Compound Amino Acid (15) Dipeptide (2) Injection issued by the National Medical Products Administration.

It is understood that the amino acids provided by the compound amino acid (15) dipeptide (2) injection are a component of parenteral nutrition therapy, suitable for patients who cannot receive nutrition orally or through the intestines, and for patients whose nutritional needs cannot be met by these routes, especially for patients with moderate to severe catabolism. This approval will further enrich Tianjin Pharmaceutical's formulation product line, strengthen the company's integrated "raw material + formulation" strategic advantage, and enhance its competitiveness in the parenteral nutrition market segment.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)